The UND technology is based on the detection of cancer biomarkers in breast nipple aspirate fluid (NAF).

UND School Department of Surgery Medicine and Health Sciences professor Ed Sauter said they identified a promising breast cancer predictive marker panel through funding from the National Institutes of Health (NIH).

"It is exciting to partner with NeoMatrix to validate our panel, in the hopes of gaining US Food and Drug Administration (FDA) approval and bringing it to clinical use," Sauter said.

NeoMatrix products include FDA-cleared HALO Breast Pap test which is the first fully automated noninvasive breast disease-screening device used for the collection of nipple aspirate fluid (NAF) for cytological evaluation.